Europe Continuous Glucose Monitoring (CGM) Market - Strategic Insights and Forecasts (2026-2031)

The European Continuous Glucose Monitoring (CGM) market is forecast to grow at a CAGR of 28.6%, reaching USD 4,314.0 million in 2031 from USD 1,226.6 million in 2026.

Key Highlights

Market Overview

The market comprises disposable sensors, reusable transmitters, receivers, integrated software platforms, and associated clinical support services. Revenue is generated through recurring sensor replacement rather than one-time equipment purchases, creating long-term supplier relationships with hospitals, diabetes clinics, pharmacies, and home care providers. Manufacturers increasingly compete through software functionality, connectivity, clinical validation, reimbursement support, and patient experience rather than hardware specifications alone.

Across Europe, reimbursement policies continue to shape market access more directly than consumer purchasing power. Countries with comprehensive reimbursement for Type 1 diabetes and selected insulin-treated Type 2 diabetes populations have recorded higher adoption than markets relying primarily on private payment. Healthcare systems are also placing greater emphasis on technologies that reduce severe hypoglycemic events, emergency admissions, and long-term diabetes complications, strengthening the economic case for wider CGM use.

Commercial opportunities remain closely linked to demographic trends and healthcare system priorities. The International Diabetes Federation estimates that approximately 66 million adults were living with diabetes across the IDF Europe region in 2024, with prevalence expected to increase over the coming decades. At the same time, European healthcare providers continue expanding digital diabetes management programs that integrate continuous glucose data into clinical decision-making, supporting recurring demand for connected monitoring technologies.

Key Market Indicators

Market Drivers

Expansion of reimbursement policies for intensive diabetes management

Public reimbursement remains one of the strongest commercial drivers for continuous glucose monitoring adoption across Europe because the technology carries recurring sensor costs that many patients would otherwise struggle to finance. National health authorities in countries including Germany, France, the United Kingdom, and Spain have progressively expanded reimbursement eligibility for patients requiring intensive insulin therapy, particularly individuals with Type 1 diabetes and selected insulin-dependent Type 2 diabetes populations. These policy decisions increasingly rely on health technology assessments demonstrating improvements in glycemic control and reductions in severe hypoglycemic episodes.

Manufacturers have responded by generating additional real-world clinical evidence and engaging with reimbursement authorities to support broader patient eligibility. Company disclosures from Abbott, Dexcom, and Medtronic consistently identify reimbursement expansion as a critical factor supporting European revenue growth. As reimbursement coverage broadens, suppliers benefit from higher recurring sensor utilization rather than isolated device sales, improving revenue visibility and strengthening long-term relationships with healthcare providers.

Increasing integration of CGM data into digital diabetes management

Healthcare providers increasingly require continuous glucose monitoring systems that exchange data seamlessly with insulin pumps, mobile applications, cloud-based clinical platforms, and electronic health records. Clinical management now depends not only on glucose measurements but also on standardized analytics that help physicians identify glycemic variability, treatment adherence, and emerging complications between scheduled consultations.

Suppliers have expanded software capabilities alongside sensor development. Dexcom, Abbott, Roche Diabetes Care, Tandem Diabetes Care, and Ypsomed continue strengthening interoperability through digital ecosystem partnerships and software integration strategies disclosed in their investor communications. Buyers increasingly evaluate cybersecurity, data sharing, clinician dashboards, and compatibility with automated insulin delivery systems alongside traditional sensor accuracy. This broader purchasing criterion increases the commercial value of integrated platforms while raising switching costs for healthcare providers already operating within established digital ecosystems.

Growing clinical emphasis on preventing diabetes-related complications

Diabetes management is increasingly measured by long-term outcomes rather than periodic glucose testing alone. Clinical guidelines across Europe encourage more frequent glucose assessment to reduce hypoglycemia, improve time-in-range metrics, and lower the risk of cardiovascular, renal, ophthalmic, and neurological complications associated with poor glycemic control. Continuous monitoring provides clinicians with substantially richer datasets than conventional finger-stick testing, supporting individualized treatment adjustments.

Healthcare systems increasingly recognize that preventing diabetes complications reduces downstream hospital admissions and treatment costs. This economic rationale has encouraged hospitals, specialist diabetes centers, and home care providers to expand CGM utilization among eligible patient populations. Manufacturers continue investing in sensor accuracy, extended wear duration, and predictive alert capabilities because these performance improvements directly support physician confidence and reimbursement acceptance.

Population ageing and rising prevalence of insulin-treated diabetes

Europe continues to experience demographic ageing alongside increasing diabetes prevalence, creating sustained demand for long-term glucose monitoring solutions. Older patients frequently require closer glycemic management because diabetes often coexists with cardiovascular disease, chronic kidney disease, and other metabolic disorders that complicate treatment decisions. Continuous monitoring enables clinicians to adjust therapy while reducing severe glucose fluctuations that may result in emergency hospitalization.

Healthcare providers are also expanding remote management models for elderly patients receiving treatment outside hospital settings. Home care organizations increasingly incorporate connected monitoring technologies that allow clinicians and caregivers to review glucose trends without requiring frequent outpatient visits. Manufacturers have responded by simplifying sensor insertion procedures, improving mobile connectivity, and extending sensor wear periods to improve patient adherence and reduce healthcare resource utilization.

Market Restraints and Challenges

Uneven reimbursement policies across European healthcare systems

Although reimbursement has expanded in several European countries, eligibility criteria continue to differ considerably between national healthcare systems. Some markets provide broad coverage for insulin-treated patients, while others restrict reimbursement to narrowly defined clinical populations or require extensive documentation before approval. These differences create uneven adoption patterns despite similar disease prevalence across countries.

Manufacturers frequently invest considerable resources in country-specific reimbursement negotiations, health economic studies, and clinical evidence generation before commercial expansion becomes viable. Smaller suppliers may find these market access requirements particularly demanding because reimbursement delays extend commercialization timelines and increase pre-revenue investment. Consequently, product availability often depends as much on reimbursement policy as technological capability.

Higher regulatory compliance costs under the European Medical Device Regulation

The implementation of the European Union Medical Device Regulation (EU MDR 2017/745) has strengthened clinical evidence, quality management, traceability, and post-market surveillance requirements for medical device manufacturers. While these measures improve patient safety and product quality, they also increase regulatory costs and extend approval timelines for new continuous glucose monitoring technologies.

Manufacturers must maintain comprehensive technical documentation, conduct ongoing clinical evaluations, and strengthen post-market surveillance throughout the product lifecycle. Larger companies generally possess greater regulatory resources, whereas smaller developers may experience longer commercialization cycles and higher compliance costs. These requirements have increased barriers to entry without eliminating competitive innovation, encouraging suppliers to prioritize regulatory planning earlier in product development.

Persistent pricing pressure from publicly funded healthcare systems

European healthcare systems continue emphasizing value-based purchasing and budget discipline when evaluating diabetes technologies. Public procurement agencies increasingly compare products using clinical performance, total treatment costs, reimbursement impact, and long-term health economic outcomes rather than device specifications alone. Suppliers therefore face continuing pressure to justify premium pricing through measurable improvements in patient outcomes.

Large manufacturers have responded by investing in clinical evidence generation, software enhancements, and integrated care solutions that strengthen value propositions beyond sensor performance. Nevertheless, sustained pricing negotiations may compress margins, particularly where procurement decisions prioritize cost-effectiveness within fixed public healthcare budgets. This commercial environment favors companies capable of combining manufacturing scale with strong clinical evidence and long-term service support.

Major Segment Analysis

Diabetes Patients

Diabetes patients represent the most commercially important application segment because continuous glucose monitoring supports day-to-day glycemic management throughout the disease lifecycle rather than during isolated clinical episodes. Demand is strongest among individuals with Type 1 diabetes and continues to expand among insulin-treated Type 2 diabetes patients as European reimbursement programs widen eligibility. Purchasing decisions are influenced by sensor accuracy, wear duration, ease of insertion, smartphone connectivity, alarm functionality, and compatibility with insulin pumps or automated insulin delivery systems.

Healthcare providers increasingly evaluate CGM solutions using clinical outcome measures such as time in range, frequency of hypoglycemic events, and patient adherence instead of relying solely on glucose accuracy. Manufacturers compete by improving sensor longevity, reducing calibration requirements, and strengthening digital health integration. Although critical care applications continue to receive clinical attention, diabetes management remains the primary source of recurring sensor demand because patients require continuous monitoring over extended periods. This recurring replacement cycle provides predictable revenue opportunities while encouraging suppliers to invest in software services, clinician support tools, and connected diabetes management ecosystems.

Regional Analysis

Germany represents one of Europe's most established continuous glucose monitoring markets, supported by a structured reimbursement framework and early adoption of digital diabetes technologies. Statutory health insurance has expanded access to CGM for eligible diabetes patients following positive health technology assessments, encouraging wider clinical use in both specialist diabetes centers and home care settings. Demand is increasingly driven by integrated diabetes management, where clinicians evaluate sensor accuracy, interoperability with insulin delivery systems, and long-term clinical outcomes alongside device cost.

The United Kingdom continues to expand CGM adoption through the National Health Service (NHS), supported by updated clinical guidance from the National Institute for Health and Care Excellence (NICE). Broader reimbursement for eligible individuals with Type 1 diabetes and selected Type 2 diabetes patients has increased procurement across hospitals, diabetes clinics, and community care settings. Healthcare providers are placing greater emphasis on remote monitoring and digital data sharing to improve treatment decisions while reducing avoidable hospital admissions associated with poor glycemic control.

France maintains a mature diabetes management infrastructure supported by national reimbursement policies administered through the public healthcare system. Market demand is influenced by clinical evidence demonstrating improvements in glycemic control, patient adherence, and reductions in severe hypoglycemic events. Suppliers seeking broader commercial penetration must satisfy stringent reimbursement and regulatory requirements while providing long-term clinical and health economic evidence that supports continued funding decisions.

Spain continues to strengthen CGM adoption through its publicly funded healthcare system, although reimbursement implementation may differ across autonomous communities. Increasing diabetes prevalence, expanding use of connected healthcare services, and greater physician acceptance of continuous monitoring technologies are supporting demand. Procurement decisions increasingly consider interoperability, patient usability, and lifecycle costs, encouraging manufacturers to offer integrated digital diabetes management solutions rather than standalone monitoring devices.

The remaining European countries, including Italy, the Netherlands, Belgium, the Nordic countries, Austria, Switzerland, and several Central and Eastern European markets, present varying levels of commercial opportunity depending on reimbursement maturity, healthcare investment, and diabetes management policies. While adoption remains uneven across these markets, gradual expansion of reimbursement programs, increasing digital health investment, and wider clinical acceptance of continuous glucose monitoring are expected to support broader regional demand during the forecast period. Manufacturers are therefore pursuing country-specific reimbursement strategies and distribution partnerships to address differences in healthcare funding, procurement practices, and regulatory implementation across Europe.

Competitive Landscape

Competition in the Europe continuous glucose monitoring market is technology-driven and moderately concentrated, with a limited number of multinational manufacturers accounting for a substantial share of commercial activity while regional specialists address selected clinical niches. Dexcom, Inc., Abbott Laboratories, Medtronic plc, Roche Diabetes Care, Tandem Diabetes Care, Ypsomed AG, Diabeloop, GlucoMen, and Diabetizer GmbH & Co. KG compete through sensor performance, software functionality, digital ecosystem partnerships, reimbursement support, and clinical evidence rather than price alone.

Abbott and Dexcom continue investing in next-generation sensors, expanded software capabilities, and broader interoperability with insulin delivery systems. Medtronic, Tandem Diabetes Care, Ypsomed, and Diabeloop increasingly strengthen automated insulin delivery ecosystems through integrated device platforms and strategic partnerships. Roche Diabetes Care continues leveraging its diabetes management portfolio and digital health capabilities to strengthen customer relationships. Smaller companies differentiate themselves through specialized technologies, regional distribution networks, or complementary diabetes management solutions. Compliance with the European Medical Device Regulation, sustained clinical evidence generation, established reimbursement expertise, and reliable post-market support remain important competitive barriers for new entrants seeking large-scale commercialization across multiple European healthcare systems.

Recent Developments

• June 2026: Medtronic introduced the Instinct continuous glucose monitoring system, developed with Abbott technology, for European MiniMed insulin pump users, providing extended wear, improved connectivity, and seamless automated insulin delivery integration.

• April 2026: Senseonics commercially launched the Eversense 365 implantable CGM in Europe, beginning in Sweden with phased rollouts in Germany, Spain, and Italy, offering the world's first one-year continuous glucose monitoring system.

• February 2026: Medtronic began the commercial EMEA rollout of the MiniMed Go Smart MDI system integrated with the Simplera CGM sensor, providing real-time glucose insights and connected diabetes management for multiple daily injection users.

• January 2026: Senseonics obtained CE Mark approval for the Eversense 365 implantable CGM, enabling commercialization throughout the European Union and introducing the first continuous glucose monitoring sensor with a 365-day wear duration.

Regulatory and Policy Environment

The European regulatory environment remains one of the most influential factors affecting continuous glucose monitoring commercialization. The European Union Medical Device Regulation (EU MDR 2017/745) requires manufacturers to demonstrate stronger clinical evidence, maintain comprehensive quality management systems, strengthen post-market surveillance, and improve product traceability throughout the device lifecycle. These obligations increase development and compliance costs but also raise confidence among healthcare providers and patients by establishing more rigorous safety and performance standards.

National reimbursement authorities continue to play an equally important role in determining commercial success. Health technology assessment agencies increasingly evaluate CGM systems using evidence relating to hypoglycemia reduction, glycated hemoglobin improvement, time-in-range performance, quality of life, and long-term healthcare costs. As a result, manufacturers must combine product innovation with robust clinical and economic evidence to secure reimbursement decisions. Professional organizations, including diabetes associations across Europe, continue updating clinical recommendations that support wider use of continuous glucose monitoring among appropriate patient populations, further influencing procurement priorities within publicly funded healthcare systems.

Outlook and Strategic Implications

The Europe continuous glucose monitoring market is expected to remain driven by recurring sensor demand, broader reimbursement coverage, and continued integration of digital diabetes management technologies. Commercial success will increasingly depend on suppliers' ability to demonstrate measurable clinical outcomes alongside reliable software performance, cybersecurity, interoperability, and long-term service capability. Hardware improvements alone are unlikely to provide sustainable competitive differentiation as purchasing decisions become increasingly outcome-based.

Several strategic priorities are expected to shape market performance during the forecast period:

• Manufacturers: Continue investing in sensor accuracy, longer wear duration, software analytics, and automated insulin delivery integration while strengthening regulatory compliance capabilities.

• Healthcare providers: Prioritize technologies that improve patient outcomes, reduce acute diabetes complications, and support remote clinical management without increasing operational burden.

• Payers and reimbursement authorities: Expand evidence-based reimbursement where long-term reductions in diabetes complications justify recurring technology costs.

• Technology partners and system integrators: Develop interoperable digital platforms that combine continuous glucose data with broader chronic disease management systems.

Companies capable of combining clinical validation, reimbursement expertise, digital integration, regulatory compliance, and dependable supply chains will be better positioned to strengthen their presence across Europe's evolving diabetes care market. As healthcare systems continue shifting toward preventive and data-driven disease management, continuous glucose monitoring is expected to become an increasingly established component of routine diabetes care rather than a technology reserved for selected patient groups.

Europe Continuous Glucose Monitoring (CGM) Market Scope: